Detalhe da pesquisa
1.
Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease.
Diabetes Obes Metab
; 24(7): 1288-1299, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35332654
2.
Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14.
Cardiovasc Diabetol
; 18(1): 156, 2019 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31729990
3.
Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials.
Diabetes Obes Metab
; 21(7): 1745-1751, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30851070
4.
Level of Physical Activity, Left Ventricular Mass, Hypertension, and Prognosis.
Hypertension
; 75(3): 693-701, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31884852
5.
Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial.
Diabetes Care
; 42(10): 1912-1920, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31399438
6.
Response to Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912-1920.
Diabetes Care
; 43(2): e30-e31, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31959650
7.
Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial.
Diabetes Care
; 43(9): e108-e110, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32647053